In 2012, Indiana civic and corporate leaders called for building a non-profit research institute that could attract world class research talent to Indiana to enable discovery science and innovation, working in collaboration with academic and industry researchers.
IBRI was initially funded with $50 million provided by the State, Lilly Endowment, Eli Lilly and Company, Roche Diagnostics, Corteva Agriscience (formerly Dow AgroSciences), Indiana University Health and Indiana University School of Medicine. In February 2016, we received an additional $100 million in funding commitments from Lilly Endowment Inc. and Eli Lilly and Company Foundation.
2017 was a year of change and growth. IBRI's staff grew from 14 to 22 employees. It's project portfolio and collaborations grew from 1 to 9. Rainer Fischer, PhD joined IBRI as the Chief Scientific and Innovation Officer (CSIO) early in the year and then assumed the role of CEO later in the year. The leadership team developed a 5-year strategic plan that was approved by the Board of Directors and a trajectory of future direction and growth for the institute was solidified.
In 2018, the IBRI significantly expanded its research capabilities, broadening its collaborations with life sciences companies and research universities. The IBRI Diabetes Center (IDC), which will eventually have new researchers and scientific teams from the IBRI-based Lilly Diabetes Center of Excellence (LDCE), a collaboration involving Eli Lilly and Company, Indiana University (IU) School of Medicine and the IBRI, was established. And, the newest research area, the Pharmaceutical Biotechnology Center (PBC), which will initially focus on the development of therapeutic antibodies and vaccines, was established. Employment grew to 35.
- Established three new labs in the IBRI Diabetes Center.
- Identified a new monogenic disease, Deoxyhypusine synthase (DHPS) disorder.
- Launched CTox, a shared platform to identify potential compound toxicity.
- Added six new scientists to the Pharmaceutical Biotechnology Center.
- Completed two technologies – SIERRA and BioMEMs – two years ahead of schedule.
- Significantly expanded research capabilities
- Broadened collaborations with life sciences companies and research universities
- Increased public and private funding
- Broke ground for new building in 16 Tech Innovation District
- Strategic framework approved
- Secured $20 million from the state
- Rainer Fischer onboarded as CSIO
- Daniel H. Robertson hired as Research Fellow and VP of Digital Technology
- Rainer Fischer assumes role of CEO
- 5-year Strategic Plan created and approved by Board of Directors
- $100 million Endowment and Lilly Foundation announcement
- Teresa Mastracci hired as first scientist
- First research projects - JDRF, Lilly, and Big Data
- Rainer Fischer hired as CSIO
- Nitesh Chawla, UND, hired as interim Director, ADS
- $1 million Cook Medical grant
- Michael Pugia hired as Fellow and Director of Single Cell Analytics Core
- Formed Scientific Advisory Board (SAB)
- Hired David Broecker as President and CEO
- Hired Advancement Director and Chief of Staff
- Opened IBRI facilities at BRTC
- Secured land and $75 million in financing for 16 Tech
- Hired Raghu Mirmira as Interim Scientific Director
- Completed IP and academic frameworks
- Received IRS tax exempt status
- Launched permanent site activities
- IBRI legal entity formed
- Board of directors named
- Secured $50 million in funding commitments